Testosterone transdermal - Acrux

Drug Profile

Testosterone transdermal - Acrux

Alternative Names: Luramist; Testosterone MDTS®; Testosterone transdermal spray - Acrux

Latest Information Update: 24 Jun 2016

Price : $50

At a glance

  • Originator Acrux
  • Developer Acrux; Fempharm; Howard Florey Institute; National Health and Medical Research Council Clinical Trials Centre
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Female sexual dysfunction

Highest Development Phases

  • Discontinued Cognition disorders; Female sexual dysfunction

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Aug 2015 Discontinued - Phase-II for Female sexual dysfunction in Australia (Transdermal)
  • 10 Aug 2010 All rights to Luramist® belong to Fempharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top